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Macrophages (Mp) are implicated in both early and late phases in type 1 diabetes development. Recent study has suggested that a
balance between reductive Mp (RMp) and oxidative Mp (OMp) is possible to regulate TH1/TH2 balance. The aim of this study is to
investigate the redox status of peritoneal Mp and its cytokine profile during the development of autoimmune diabetes induced by
multiple low-dose streptozotocin in BALB/c mice. Meanwhile, the polarization of TH1/TH2 of splenocytes or thymocytes was also
examined. We found that peritoneal Mp appeared as an “incomplete” OMp phenotype with decreased icGSH along with disease
progression. The OMp showed reduced TNF-α, IL-12, and NO production as well as defective phagocytosis activity compared to
nondiabetic controls; however, there was no significant diﬀerence with IL-6 production. On the other hand, the levels of IFN-γ or
IL-4 of splenocytes in diabetic mice were significantly higher compared to the control mice. The ratio of IFN-γ to IL-4 was also
higher at the early stage of diabetes and then declined several weeks later after the occurrence of diabetes, suggesting a pathogenetic
TH1 phenotype from the beginning gradually to a tendency of TH2 during the development of diabetes. Our results implied that
likely OMp may be relevant in the development of type 1 diabetes; however, it is not likely the only factor regulating the TH1H/TH2
balance in MLD-STZ-induced diabetic mice.
INTRODUCTION
Macrophages (Mp) play a pivotal role in specific and
nonspecific immunity, and the physiological status of
Mp may contribute to the overall regulation of the host
defense system. A number of studies have showed the
functional heterogeneity of Mp with diﬀerent cytokine
propensity or metabolic activities, therefore inducing dis-
tinct immune response such as TH1-type versus TH2-type
(TH, T helper). Very recently, Murata et al proposed the
functional discrimination of two classes of Mp, namely
the reductive Mp (RMp) with a high intracellular con-
tent of glutathione (icGSH) and oxidative Mp (OMp)
with a reduced content [1]. It was found that TH1/TH2
balance might be regulated by the altered balance be-
tween RMp and OMp through the distinctive production
of TNF-α, IL-12, and NO (nitric oxide) versus IL-6 and
IL-10. This classification cast light on the potential role
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of the predominant RMp or OMp in inflammatory and
autoimmune diseases, such as IDDM (insulin-dependent
diabetes mellitus) in NOD (nonobese diabetic) mice [2],
spontaneous inflammatory bowed disease [3], cancer im-
munotherapy [4], corneal allograft [5], and aging-related
autoimmune disease [6]. To date, the predominant pres-
ence of RMp or OMp in the development of multi-
ple low-dose streptozotocin (MLD-STZ) induced diabetes
has been little studied.
For our experiments, we used the MLD-STZ animal
model. Recently this model has been attractive for its little
or no influence of genetic background, as most new cases
of type 1 diabetes are sporadic and occur in families with
no previous history of diabetes. Furthermore, as the term
“latent autoimmune diabetes mellitus in adults” (LADA)
has been introduced to describe an important minority of
adult-onset patients with diabetes [7], STZ-induced dia-
betic mice may serve to be a better model of it since di-
abetes can be initiated at a relatively older age, when an-
imals had all reached maturity, with a negligible weight
loss.
Using this murine model, we found that during
the development of diabetes, peritoneal Mp consis-
tently skewed to OMp with gradually decreased icGSH.
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The OMp showed reduced TNF-α, IL-12, and NO pro-
duction, and also defective phagocytosis activity com-
pared to nondiabetic controls, although there was no sig-
nificant diﬀerence with IL-6 production. On the other
hand, the levels of IFN-γ or IL-4 of splenocytes in diabetic
mice were significantly higher than the controls. The ra-
tio of IFN-γ to IL-4 level was higher at the early stage of
diabetes, then declined several weeks later after the occur-
rence of diabetes, concomitant with the sequential change
of TH1/TH2 skewing in the thymus. Thus, the aberrant
OMp might play a relevant role in the pathological pro-
gression of diabetes, however, it is not likely the only fac-
tor regulating the TH1/TH2 balance inMLD-STZ-induced
diabetes mellitus.
MATERIALS ANDMETHODS
Experimental animals
Male BALB/c mice were initially purchased from
Shandong Laboratory Animal Center and bred in our lab-
oratory animal facility. The mice were housed with free
access to water and a standard laboratory diet. Diabetes
was induced in mice with STZ (Sigma, St Louis, Mo) as
described previously [8]. Briefly, STZ was reconstituted
in 25mM sodium citrate (pH 4.5). Injections were made
intraperitoneally (40mg/kg, IP) within 15 minutes of
preparation. Mice were treated with five consecutive daily
injections. Nonfasting blood glucose levels were measured
once a week, following the administration of STZ by a
blood glucose monitor drawing blood from the tail vein
(Lifescan, Inc, Milpitas, Calif). Mice with a blood glucose
of at least 11.1mmol (300mg/DL) were induced gradu-
ally after 3 weeks following MLD-STZ of BALB/c mice;
those that became diabetic within 1 week were used as di-
abetic group in the experiment (n = 6; blood glucose:
15±2.1mmol; body weight: 28±1.9 g), while those that
became diabetic over 4 weeks were used as advanced di-
abetic group (n = 6; blood glucose: 20±2.5mmol; body
weight: 25±2.9 g). Mice given the same amount of 25mM
citrate buﬀer were used as the control group (n = 6; blood
glucose: 5+/−0.4mmol; body weight: 28+/−1.5 g). Even
to advanced diabetes mice, there was no significant loss in
body weigh compared with the controls.
Proliferation assay
The thymus cells or spleen cells proliferation as-
say on stimulation of ConA (Conconavalin A) was
measured using MTT (3-(4,5-dimethylthiazal-2-yl)-2,5-
diphenyltetra-zolium bromide) reduction assay as previ-
ously described [9]. Briefly, Single cell suspensions of ei-
ther thymocytes or splenocytes were prepared and via-
bility was assessed by trypan blue exclusion. Thymocytes
(8×105 cells/well) or splenocytes (4×105 cells/well) were
plated in 96-well plates in RPMI-1640 (medium named
after Roswell Park Memorial Institute) complete medium
and were stimulated with ConA (30 ug/ml, Sigma) for 20
hours or 44 hours. Sterile MTT solution (5mg/ml MTT
in RPMI-1640) was then added into the wells and incu-
bated for another 4 hours until purple precipitate was vis-
ible. After moving themedium by centrifugation, the con-
verted dye was solubilized with 200UL dimethyl sulphox-
ide, and the absorbance of the converted dye was mea-
sured at a wavelength of 490 nm with background sub-
traction as 630 nm. The stimulation index (SI) is de-
termined by the absorbance with ConA/the absorbance
without ConA.
Peritonealmacrophages
Peritoneal cells (PC) were harvested by injecting to-
tal 10mL of an ice-cooled Hanks-10% FBS (fetal bovine
serum)-heparin (10U/mL) solution into the peritoneal
cavity of mice. The collected PCs were added to a mi-
croplate at 1–3 × 105 cells/200 uL RPMI-1640 medium.
The adherent cells after a 2-hour incubation were used as
resident peritoneal Mp for production of cytokines and
NO by culturing for 48 hours.
Determination of intracellular GSH
Peritoneal cells adherent to dishes were collected by
D-Hanks (2.5mmol/L EDTA) and washed 3 times with
cold D-hanks buﬀer. The cell pellet was immediately lysed
with ultrasonic, and after centrifugation, some of the su-
pernatants was assayed for the total protein content using
the Coomassie protein assay kit (Jiancheng Co, Nangjing,
China). Thereafter, 10% sulfosalicylic acid was added to
the remained supernatants to precipitate protein. After
centrifugation, supernatants were collected for GSH as-
say. The cellular GSH concentration was assayed using the
GSH kit (Jiancheng Co), and the icGSH was determined
as mg GSH/g protein.
Nitrite assay
The accumulation of NO2 was taken as a parameter
for nitrite (NO) production. NO production by Mp was
measured in supernatants collected after 48 hours of cul-
ture. Briefly, cell-free supernatants were incubated with
the Griess reagent for 10 minutes at room temperature
and absorbance at 550 nm was measured. The concentra-
tion of NO2 was determined by the square linear regres-
sion analysis of a sodium nitrite standard that was mea-
sured in each experiment.
Measurement of cytokine levels by ELISA
The IL-4, IL-6, TNF-α, and IFN-γ concentration was
determined using an ELISA (enzyme-linked immunosor-
bent assay) kit (Alpha Diagnostic Intl, Inc, San Antonio,
Tex) according to the indication of the manufacturer.
Phagocytosis assays
The phagocytosis activity of Mp was measured by the
neutral fuchsin uptake method. 0.075% neutral fuchsin
solution was added to adherentMp (5×106 cells/mL), and
the samples were incubated for 1 hour at 37◦C to study
phagocytosis. Cells were then subjected to lysis by adding
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Figure 1. The periodic change of peritoneal Mp. (a) Mp count.
There was significant diﬀerence between the diabetic and control
groups (P < .05), and the count increased significantly after the
onset of diabetes (P < .01). (b) The amount of intracellular GSH
in adherent Mp of the mice. Mp collected from the diabetic mice
showed significantly decreased content compared to that of con-
trol Mp. Results shown are representative of three experiments,
and the Mp were all resting Mp.
lysis solution (0.1 N acetic acid: ethanol = 1: 1, v/v) after
washing 3 times to get rid of externally red dye. The ab-
sorbance of the cell lysis at 570 nm was measured, and the
phagocytosis activity is determined by A value.
Statistical analysis
The results of icGSH levels, NO content, macrophage
phagocytosis, ConA-stimulated index, and cytokine levels
were expressed as mean +/- SE. This data was analyzed by
Student’s t test, and the diﬀerence was judged at P < .05.
RESULTS
The Mp count was significantly increased in the
peritoneal cavity of diabetic mice (4.5+/−2.21 ×
106 cells/mouse) as compared to nondiabetic controls
(1.1+/−0.59 × 106 cells/mouse) (P < .05), and the Mp
continued to increase 4 weeks after the incidence of
diabetes (5.4+/−1.46 × 106 cells/mouse) (Figure 1a). In
addition, the redox status of Mp, indexed by icGSH, was
significantly decreased in either early (28+/−6.6mg/g
protein) or advanced diabetic mice (12+/−3.3mg/g
protein) as compared to the controls (62+/−3.4mg/g
protein) (Figure 1b). Significant diﬀerence was also found
between the (early) diabetic mice and the advanced
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Figure 2. Graphical representation of cytokine quantitation
(TNF-α, IL-12, and IL-6) in conditioned medium fromMp cul-
tures (106 cells/mL) on in vitro stimulation of LPS (40mg/L) af-
ter 36 hours. The graph is generated from four separate exper-
iments. There were significant diﬀerences between control and
experimental groups. Note that all cytokines of Mp except IL-6
exhibited a significant reduction in diabetic mice.
diabetic ones. Therefore, along with the diabetic progres-
sion, the peritoneal Mp showed OMp phenotypes with
gradually decreased icGSH.
To characterize the cytokine expression profile by the
OMp in diabetic mice, we assessed cytokines that have
been found to be related to OMp or RMp, namely, TNF-
α, IL-12, IL-6, and NO. As expected, levels of TNF-α, IL-
12, and NO exhibited a significant reduction in diabetic
mice compared with the controls, however, IL-6 remained
unchanged instead of being upregulated (Figure 2). The
observed reduced cytokine expression was consistent with
the decreased amount of intracellular GSH in diabetic Mp
except IL-6, which would show an elevated production in
OMp according to its definition [1].
There is clear evidence that Mp play an essential role
in the provocation of autoimmune diabetes. In order to
determine whether the OMp in diabetic mice are associ-
ated with aberrant Mp function, we examined the phago-
cytic ability of the peritoneal Mp using the neutral fuchsin
uptake method. It was found that STZ treatment sup-
pressed the phagocytosis activity of the peritoneal Mp
markedly (Figure 3), though there was no marked diﬀer-
ence between the early and the advanced phases of dia-
betes.
Besides the alteration in immune mediator release,
we also observed evident morphological changes in cul-
tured Mps. During culture (within 7 days), normal Mp
increased in size and diﬀerentiated from a homogeneous
round shape into a morphologically heterogenenous pop-
ulation of fusiform- and epithelioid-shaped Mp. But in
diabetic mice, the majority of Mp remained undiﬀerenti-
ated (data not shown).
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Figure 3. Spleen cell and thymus cell proliferation and cytokine secretion. (a) Spleen cell and thymus cell proliferation (assessed at 24
hours) in response to mitogen stimulation was aﬀected by STZ treatment, and the stimulation indexes in the diabetic groups are all
higher than the control, though not always significant. (b) Thymocytes or (c) splenocytes were stimulated with ConA (30 µg/mL) for
48 hours before collection of conditioned medium. IL-4 and IFN-γ concentrations following stimulation were determined by ELISA.
(d) The periodic change of TH1/TH2 balance during disease progression.
The balance of TH1/TH2 responses has been recog-
nized as a critical factor in the development of type 1 di-
abetes, and it is well established that diabetes is associated
with the development of a pathogenic TH1 response [10].
However, it remains to be determined whether the TH1
response varies during disease progression, and whether
the variation is concomitant with the change of Mp phe-
notype in (multiple low-dose streptozotocin) MLD-STZ-
induced diabetes model. In the succeeding experiments,
the TH1/TH2 balance of T cells in the spleen and thymus
was analyzed. The unfractionated splenocytes or thymo-
cytes were in vitro stimulated with ConA, and the pro-
liferative response of cells and the cytokine levels were
measured. After stimulation, the proliferative response of
splenocytes or thymocytes was found to be higher in some
sort than that of controlmice (Figure 4a), accompanied by
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Figure 4. Defective phagocytic activity in diabetic mice is shown. Peritoneal Mp were harvested from the abdominal cavities of mice
injected 72 hours earlier with liquid paraﬃn, the cells were adjusted to 5 × 106 cells/mL per well, and the ability of uptaking neutral
fuchsin is indicated by A value at 570 nm.
secreting much more cytokines of IL-4 and IFN-γ (Fig-
ure 4b, 3c). Though it appeared rather complicated in
the cytokines change, the ratio of IFN-γ to IL-4 showed
a similar tendency in the thymus or in the spleen, with the
significantly high IFN-γ/IL-4 ratio (TH1 type phenotype)
declining gradually during the disease progression (Figure
3d).
DISCUSSION
In line with the increasing evidence claiming the cen-
tral role of innate over adaptive immune responses, a
paradigm has been proposed on the presence of func-
tional heterogeneity of Mp. Murata et al have divided Mp
at least into two activated states based on their icGSH
[1], and the role of intracellular redox status of Mp in
regulating TH1/TH2 balance has been discussed widely
[2, 3, 4, 5, 6]. However, to the author’s knowledge, there
is little information available in literature about the re-
dox status of Mp in diabetic mice induced by MLD-STZ.
In the present study, we conducted this study to deter-
mine whether the redox status of Mp and their cytokine
production change during the development of diabetes in
BALB/c mice and, additionally, if the change of the redox
status of Mp is concomitant with the change of TH1/TH2
skewing in the spleen or the thymus. The results indi-
cated that the peritoneal Mp were consistently skewed to
OMp dominance during the disease progression, tending
to produce declined cytokine expression of TNF-α, IL-12,
and NO compared to those from nondiabetes controls.
However, the diabetic OMp phenotype showed its ab-
normalities somehow characterized by its unchanged IL-6
levels and significantly reduced phagocytic activity com-
pared with the defined OMp. On the other hand, the thy-
mus cells and spleen cells exhibited a diﬀerent TH1/TH2
balance shift, with a TH1 type on the onset of diabetes,
converting to TH2 phenotypes several weeks later after di-
abetes occurred. The data reported here might imply that
multifactor dysfunction, rather than aberrant OMp alone,
may cooperate to precipitate TH1/TH2 imbalance of dia-
betic mice induced by MLD-STZ.
Streptozotocin (STZ), a potential source of oxidative
stress, can penetrate into the organism generating NO and
thus inducing genotoxicity [11]. It has appeared that STZ
treatment generally induces an oxidative predominance
in murine tissues, including liver, kidney, heart, lungs,
spleen, brain, muscles, and pancreas, with decreased GSH
values and increased lipid peroxidation [12]. We exam-
ined the redox status of the peritoneal Mp in MLD-STZ
diabetes model and gained the similar results that OMp
phenotype was dominant during the development of di-
abetes, consistent with the progressive decrease in GSH
concentration of the serum (data not shown). This phe-
nomenon is compatible with the findings of Carmen that
a significant decline is observed in blood GSH content at
the recent onset of type 1 diabetes patients, and progres-
sive GSH depletion during diabetes evolution [13]. It is
noteworthy that OMp induced by STZ treatment is not
completely in accordance with the defined OMp in con-
sideration of the rather unaltered IL-6 production. We
presumed that Mp from diabetic mice might be damaged
resulting from the toxic STZ, thus leading to an aberrant
or “incomplete” OMp accompanied by the lower GSH
content. Though the pathogenic mechanism of diabetic
OMp remains elusive, one possibility is the forced infil-
tration of Mp into pancreas or other issues by modulat-
ing the chemotaxis of Mp. The redox status of Mp is sug-
gested to be a crucial determinant in the regulation of the
chemokine system. Saccani et al have described that H2O2
and the GSH-depleting drug, buthionine sulfoximine, can
increase CCR2, CCR5, and CXCR4 mRNA expression to
diﬀerent extents and the cell migration (3-fold) in re-
sponse to macrophage inflammatory protein-1beta in hu-
man monocytes [14]. Similar to it, a certain subset of Mp
selectively produces C-C chemokines [15] and the redox
status aﬀects the expression of adhesion molecules critical
for trans-endothelial migration of the inflammatory cell
[16].
There is a growing body of evidence that aberrant
cytokine production in Mp is part of a complex path-
way mediating autoimmune diabetes. However, previous
studies exploring inflammatory cytokine production by
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Mp have not always reported consistent results [10, 17,
18]. Our data showed the generally reduced cytokine pro-
duction of TNF-α, IL-12, and NO from diabetic OMp
upon in vitro LPS (lipopolysaccharide) stimulation. How-
ever, in consideration of the increasing peritoneal Mp
count in the diabetic mice, the total amount of each in-
flammatory mediator above is significantly higher than
that of the control mice (data not shown). As larger
amount of immune cells, including Mp, is also found in
the islets of Langerhans in autoimmune diabetes, it is nec-
essary to be determined whether the deficient cytokine ex-
pression itself or its relatively excessive production is rele-
vant to the pathogenesis in diabetic Mp.
Deficiencies in phagocytosis have been associated with
and may participate in the pathogenesis of both systemic
and organ-specific autoimmune diseases [19]. In our an-
imal model, we also found a significant decline in the
phagocytosis activity of Mp, a possible outcome resulting
from the oxidative status in diabeticMp [20]. Yamada et al
assessed the relationship between the proportion of oxida-
tive peritoneal exudate cells (PEC) and the β-cell destruc-
tion, and suggested the proportion of the oxidative PEC
as a novel marker of disease activity [21]. As clearance
of dying cells is critical to the control of inflammation,
engulfment of cells dying by apoptosis must occur prior
to cell lysis to prevent the release of intracellular contents
and possibly the generation of new antigens. So a defect
in the phagocytosis may be contributory to the initiation
of autoimmunity.
A number of studies have correlated diabetes with TH1
phenotype development in the MLD-STZ diabetic animal
model [8, 22, 23, 24, 25]. However, similar to other mod-
els of type 1 diabetes, some reports argued against this
oversimplification. Muller et al demonstrated that MLD-
STZ stimulated the production of IL-4 and IL-10, but
significantly reduced IFN-γ and TNF-α levels in islets of
BALB/c mice of both genders [26]. Similarly, Sitasawad
indicated that both IFN-γ and IL-4 mRNA expression in-
creased in the MLD-STZ diabetic pancreas [27]. Ins-IFN-
γ transgenic mice showed apparent resistance to the in-
duction of severe diabetes after STZ treatment compared
to the control BALB/c mice [28]. In our study, the Th
polarization in the spleen or the thymus varied during
disease progression, with TH1 phenotype dominant on
the onset of disease converting to TH2 phenotype several
weeks after diabetes occurred. The factors dictating po-
larization to TH1 phenotypes at the early stage of diabetes
remain elusive. Also, it is uncertain whether the OMp par-
ticipate in the conversion of TH1 to TH2 along with dis-
ease progression. Previous study in NOD mice showed a
similar TH1/TH2 conversion while with a consistent se-
quential change of RMp/OMp skewing [2]. In contrast
to the change style, another report suggested a converse
TH1/TH2 skewing in NOD or BBmodel, as TH2-mediated
attack is responsible for the early phase of IDDM, while
TH1-driven responses are responsible for the persistent
and sustained attacks [29]. These findings together may
suggest that the TH1/TH2 shift contributes to a patholog-
ical process, which may be dictated by multiple factors,
which would include the factors precipitating the disease,
the local APC (antigen-presenting cell) function, and the
genetic background of a given strain.
Besides the controversial TH1/TH2 polarization, there
have been also conflicting reports regarding lymphocyte
proliferative responses to mitogen either in NOD mice or
in MLD-STZ-induced diabetic mice [9, 30, 31]. Here we
showed a higher proliferative response of T cells (unfrac-
tionated splenocytes or thymocytes) in the diabetic mice,
though not always significant, compared to the controls,
in accordance with the exuberant cytokine production.
One possibility is the toxic eﬀect of STZ treatment on
the subset of lymphocytes. Further experiments should
be conducted to examine the expression of cell surface
markers, especillay the regulatory T-cell (Treg) marker of
CD4+CD25+, for a loss in the number of Treg may con-
tribute to the highly activated proliferative response. It is
also under discussion whether the defective function in
Mp or other APC might lead to the defective stimulation
of Treg cells, thus aﬀecting the proliferative response of
lymphocytes [32]. Interestingly, a recent report suggested
that the oxidation of the cellular thiol pool in T cells may
play a role as an amplifying mechanism for TCR/CD3 sig-
nals in immune response [33]. It may thus provide a new
insight into the abnormal lymphocyte functions under
the oxidative stress inMLD-STZ-induced diabetes. There-
fore, to clarify this point, experiments exploring the alter-
ation of lymphocyte function with altered icGSH in lym-
phocytes of the STZ-treated mice should be carried out in
the future.
In conclusion, our results presented the progressive
OMp phenotype in the STZ-induced diabetic mice, and
the change of TH1/TH2 skewing during the disease pro-
gression in the thymus and spleen. The data here im-
plied that OMp may be relevant in the development of
type 1 diabetes, however, it is not likely the only fac-
tor regulating the TH1/TH2 balance inMLD-STZ-induced
diabetic mice. Previous studies regarding the pathogen-
esis of oxidative stress mainly focus on the β-cell de-
struction by reactive oxygen species (ROS). However, our
study showed that the oxidative stress induced by STZ
treatment could convert the peritoneal Mp to OMp phe-
notype with a generalized decrease in cytokine produc-
tion and defective function. In addition, significant dif-
ference was also observed in either the blastogenesis of
the splenocytes or the cytokine expression profile in the
thymus and the spleen during the development of dia-
betes. This implies that the STZ-treatment damage in the
immune cells besides Mp mediated by oxidative stress
might also involve in the pathogenesis of type 1 dia-
betes. In future studies it is needed to be elucidated that
to which extent the abnormal immune cells contribute
to the pathogenesis and whether the redox regulation of
the immune cells could prevent the incidence of type 1
diabetes.
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